Title: Protocol for a sequential, prospective meta-analysis to describe coronavirus disease

2019 (COVID-19) in the pregnancy and postpartum periods

Emily R. Smith[1], Erin Oakley[1], Siran He[1], Rebecca Zavala[1], Kacey Ferguson[1], Lior Miller[1], Gargi

Wable Grandner[1], Ibukun-Oluwa Omolade Abejirinde[2], Yalda Afshar[3], Homa Ahmadzia[4], Grace

Aldrovandi[5], Victor Akelo[6], Beth A. Tippett Barr[6], Elisa Bevilacqua[7], Justin S. Brandt[8], Natalie

Broutet[2], Irene Fernández-Buhigas[9, 10], Jorge Carrillo[11], Rebecca Clifton[12], Jeanne Conry[13],

Erich Cosmi[14], Camille Delgado-López[15], Hema Divakar[16], Amanda J. Driscoll[17], Guillaume

Favre[18], Valerie Flaherman[19], Christopher Gale[20], Maria M. Gil[9, 10], Christine Godwin[2, 21], Sami

Gottlieb[2], Olivia Hernandez Bellolio[22], Edna Kara[2], Sammy Khagayi[23], Caron Rahn Kim[2], Marian

Knight[24], Karen Kotloff[17, 29], Antonio Lanzone[25, 26], Kirsty Le Doare[27, 28], Christoph Lees[29], Ethan

Litman[4], Erica M. Lokken[30, 31], Valentina Laurita Longo[26], Laura A. Magee[32, 33], Raigam Jafet

Martinez-Portilla[34, 35], Elizabeth McClure[36], Torri D. Metz[37], Deborah Money[38], Edward Mullins[29],

Jean B. Nachega[39, 40, 41], Alice Panchaud[42, 43], Rebecca Playle[44], Liona C. Poon[45], Daniel

Raiten[46], Lesley Regan[47], Gordon Rukundo[48], Jose Sanin-Blair[49], Marleen Temmerman[50], Anna

Thorson[2], Soe Soe Thwin[2], Jorge E. Tolosa[49, 51, 52], Julia Townson[44], Miguel Valencia-Prado [53],

Silvia Visentin[14], Peter von Dadelszen[32, 54], Kristina Adams Waldorf[30, 31], Clare Whitehead[55],

Huixia Yang[56], Kristian Thorlund[57], and James M. Tielsch[1]

1   Department of Global Health, George Washington University Milken Institute School of

Public Health, Washington, DC, USA

2   Department of Sexual and Reproductive Health and Research, World Health Organization,

Geneva, Switzerland

Division of Maternal Fetal Medicine, University of California Los Angeles, Los Angeles, CA, United States

Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Sciences

Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA

US Centers for Disease Control and Prevention, Kisumu, Kenya

Department of Women and Child Health, Women Health Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy

Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain.

School of Medicine, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain

Departmento de Obstetricia y Ginecologia, Clinica Alemana de Santiago, Facultad de Medicina Clinica Alemana-Universidad del Desarrollo, Santiago, Chile

Biostatistics Center, The George Washington University, Washington, DC, USA

OBGYN, The International Federation of Gynecology and Obstetrics, London, United Kingdom

Department of Woman's and Child's Health, Obstetrics and Gynecologic Clinic, University of Padua, Padua, Italy

Surveillance for Emerging Threats to Mothers and Babies, Puerto Rico Department of Health, San Juan, Puerto Rico

Asian Research and Training Institute for Skill Transfer (ARTIST), Bengaluru, India

Center for Vaccine Development and Global Health, University of Maryland, School of Medicine, Baltimore, MD, USA

Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University Hospital, Lausanne, Switzerland

Department of Pediatrics, University of California San Francisco, CA, San Francisco, USA

Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom

Global Health Research, FHI 360, Durham, NC, USA

Gynecology and Obstetrics, Felix Bulnes Hospital and RedSalud Clinic, Santiago, Chile

Kenya Medical Research Institute-Center for Global Health Research, Kisumu Kenya

National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

Department of Women and Child Health, Women Health Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy

Catholic University of Sacred Hearth, Rome, Italy

Medical Research Council /Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda

Pediatric Infectious Diseases Research Group, St. George's University of London, United Kingdom

Department of Metabolism, Digestion, and Reproduction, Imperial College London, United Kingdom

Department of Obstetrics and Gynecology, School of Medicine, University of Washington, USA

Department of Global Health, School of Public Health, University of Washington, Washington, USA

Department of Women and Children's Health, School of Life Course Sciences, King's College London, United Kingdom

Institute of Women and Children's Health, King's College Hospital, London, UK

Clinical Research Division, National Institute of Perinatology, Mexico City, Mexico

ABC Medical Center, Fetal Surgery Clinic, Mexico City, Mexico

Division of Statistics and Epidemiology, RTI International, NC, USA

University of Utah Health, USA

Department of Obstetrics and Gynecology, The University of British Columbia, Vancouver, Canada

Department of Epidemiology and Center for Global Health, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne Switzerland

Center for Trials Research, Cardiff University, Wales, United Kingdom

Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong

Pediatric Growth and Nutrition Branch, National Institute of Health, Bethesda, MD, USA

Federation International Federation Gynaecology & Obstetrics, Imperial College London United Kingdom

PeriCovid (PREPARE) – Uganda Team, Makerere University – Johns Hopkins University Research Collaboration, Uganda

Maternal Fetal Unit. Universidad Pontificia Bolivariana. RECOGEST Study. Colombia.

Department of Obstetrics and Gynecology, Aga Khan University, Nairobi, Kenya

Department of Obstetrics and Gynecology, Maternal Fetal Medicine, Oregon Health and Science University, Portland, OR, USA

St. Luke's University Health Network, Department of Obstetrics & Gynecology, Maternal Fetal Medicine, Bethlehem, PA, USA

Children with Special Medical Needs Division, Puerto Rico Department of Health, San Juan, Puerto Rico

Global Health Institute, King's College London, United Kingdom

Department of Maternal Fetal Medicine, University of Melbourne, Royal Women's Hospital, Parkville, VIC, Australia

Health Science Center, Peking University, Beijing, China

111   57 Department of Health Research Methods Evidence and Impact, McMaster University,

112   Hamilton, ON, Canada

115   ***Corresponding Author**:

116   Email: EmilySmith@gwu.edu (ES)

Abstract

We urgently need answers to basic epidemiological questions regarding SARS-CoV-2
infection in pregnant and postpartum women and its effect on their newborns. While many
national registries, health facilities, and research groups are collecting relevant data, we need a
collaborative and methodologically rigorous approach to better combine these data and address
knowledge gaps, especially those related to rare outcomes. We propose that using a sequential,
prospective meta-analysis (PMA) is the best approach to generate data for policy- and practice-
oriented guidelines. As the pandemic evolves, additional studies identified retrospectively by the
steering committee or through living systematic reviews will be invited to participate in this PMA.
Investigators can contribute to the PMA by either submitting individual patient data or running
standardized code to generate aggregate data estimates. For the primary analysis, we will pool
data using two-stage meta-analysis methods. The meta-analyses will be updated as additional
data accrue in each contributing study and as additional studies meet study-specific time or data
accrual thresholds for sharing. At the time of publication, investigators of 25 studies, including
more than 76,000 pregnancies, in 41 countries had agreed to share data for this analysis.
Among the included studies, 12 have a contemporaneous comparison group of pregnancies
without COVID-19, and four studies include a comparison group of non-pregnant women of
reproductive age with COVID-19. Protocols and updates will be maintained publicly. Results will
be shared with key stakeholders, including the World Health Organization (WHO) Maternal,
Newborn, Child, and Adolescent Health (MNCAH) Research Working Group. Data contributors
will share results with local stakeholders. Scientific publications will be published in open-access
journals on an ongoing basis.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to over 244 million confirmed cases of coronavirus disease 2019 (COVID-19) and claimed more than 4.9 million lives globally, as of October 2021 [1], and these are likely underestimates [2]. The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) note that pregnant women may be at higher risk of developing severe illness due to COVID-19 [3,4]. The specific mechanisms for this increased risk are unknown, though may be related to physiologic and immunologic changes during pregnancy. Pregnant women are generally at increased risk for severe illness from many infectious diseases including influenza, hepatitis E, malaria, and herpes simplex virus [5]. Additionally, other coronaviruses such as severe acute respiratory syndrome (SARS) are thought to pose higher risks for adverse outcomes to pregnant people; although there is only a single case-control study comparing 10 pregnant to 40 non-pregnant SARS patients [6,7].

Pregnant women with COVID-19, and their offspring, may be at increased risk for complications due to severe illness and adverse pregnancy outcomes. A living systematic review suggests that pregnant women with COVID-19, compared to non-pregnant women with COVID-19, are more than twice as likely to be admitted to an intensive care unit (ICU) or require invasive ventilation [8]. In an observational cohort study of 1,219 pregnant women across 33 U.S. hospitals with positive SARS-CoV-2 test (molecular or antigen) at the time of delivery, severe or critical COVID-19 was associated with a 40% increase in hypertensive disorders of pregnancy and a 42% increase in preterm birth, as compared to asymptomatic pregnant patients [9]. A multi-national case-control study (INTERCOVID) including 706 pregnant women with COVID-19 and 1,424 pregnant women without COVID-19 found that COVID-19 diagnosis was associated with increased risk of preeclampsia and eclampsia, severe infections, intensive care unit (ICU) admission and death [10]. A pooled analysis of 41 studies including 3323

pregnant women with COVID-19 found that one-third of their newborns were admitted to the

neonatal intensive care unit (NICU); a meta-analysis of ten studies found that newborns born to

pregnant women with COVID-19 were nearly five times more likely to be admitted to the NICU

as compared to COVID-19 negative pregnancies [8]. Reports of mother-to-child transmission of

SARS-CoV-2 during the antepartum, intrapartum, or early postnatal period remain limited.

Despite the urgent need to accurately document the number of cases, severe illness,

and deaths in pregnant women, available data on maternal and infant complications related to

COVID-19 remain heterogenous [11]. The high degree of heterogeneity in study designs,

comparison groups, and definitions of key health outcomes across studies makes it difficult to

clearly understand any excess risks and guide policy for pregnant and postpartum women and

their newborns. For example, the current (February 2021) living systematic review on COVID-19

in pregnancy included 192 studies with 64,676 pregnant and postpartum patients; the

heterogeneity in published outcomes meant that only a small fraction of those studies could be

combined for key analyses, and data from some regions of the world, (e.g., sub-Saharan Africa)

were absent. For example, data were available from only a handful of studies to examine a few

risk factors for a single outcome (severe COVID and death), and there were fewer than 10

studies that compared the risk of maternal, fetal, and newborn outcomes between pregnant and

postpartum patients versus either pregnant patients without COVID-19 or nonpregnant women

of reproductive age with COVID-19 [8]. Further, we have limited data on the efficacy of

treatments and preventives in pregnancy and postpartum, due largely to the systematic

exclusions of pregnant people from the relevant clinical trials until recently. The same was true

of the seminal vaccine trials, although vaccine studies among pregnant women began in early

2021   (ClinicalTrials.gov   Identifier: NCT04754594)   [12].   Establishing   mother-to-child

transmission of SARS-CoV-2 has also been challenging because consensus was lacking on

case definition for intrauterine, intrapartum or early postpartum transmission of SARS-CoV-2

until February 2021 [13], and all proposed definitions have required clinicians and researchers

to follow specific testing protocols [14–18].

COVID-19 data in pregnancy and infancy was scarce at first, and now it is

heterogeneous. These shortcomings exist in part because data collection protocols have

differed, and the underlying population risks for severe illnesses vary globally. It is therefore

necessary to generate high-quality information with a unified data harmonization plan and

analytic strategy. This approach will permit us to make evidence-driven decisions and to create

guidelines for the prevention and treatment of COVID-19 in pregnant women. Because little of

the existing data can be pooled, our ability to make strong recommendations related to COVID-

19's risks in pregnancy and the postpartum period is limited. We are similarly constrained in our

capacity to offer guidance as to the potential benefits of new interventions, like vaccines. So we

propose to fill this gap by conducting a sequential prospective meta-analysis (PMA). This PMA

will be a robust, collaborative, global approach to accrue harmonized data, with the objective of

generating policy and practice-relevant data about the epidemiology of COVID-19 in the

pregnancy and postnatal periods.

Methods
210

The protocol for this serial prospective meta-analysis was registered with PROSPERO

(ID: 188955) on May 28, 2020. A prospective meta-analysis identifies studies that will contribute

data to the meta-analysis, as well as establishes the analysis plans, before the results of the

individual studies are known [19]. This approach is similar to a multi-site registry or cohort in the

sense that studies work to harmonize collection of key outcomes, but differs from multi-site

studies in that each site implements a study design and local protocol that is appropriate for

their context [19]. Our goal is to provide a maximally flexible, robust, collaborative, and inclusive

analysis framework that is methodologically appropriate.

220   Ethical Approval

221   All individual study sites will obtain appropriate ethical approval for their independent

222   data collection activities. As this project is a meta-analysis using aggregate study estimates or

223   analyses of secondary, de-identified individual patient data, it is not classified as human

224   research and thus is exempt from IRB approval.

226   Language

227   Not all those who are pregnant or give birth identify as women. We use the terms

228   "pregnant women" and "pregnant people" throughout. This accurately reflects both study

229   designs (e.g. a comparison group including those who self-report as women between the ages

230   to 15 and 45) and the language used by the studies contributing data.

232   Research Questions

The study aims to answer basic epidemiological questions about COVID-19 and its

impact on maternal and newborn health by pooling data from independent studies using

harmonized data definitions and an individual patient data meta-analytic framework to minimize

data variability.

Analyses will be performed in three groups. First, we will provide descriptive statistics among

pregnant women with COVID-19. To understand the relative risks associated with COVID-19 in

pregnancy, we will compare pregnant people with COVID-19 to i) other pregnant people without

COVID-19 and ii) non-pregnant women of reproductive age (15-45 years) with confirmed or

suspected COVID-19.

Specific objectives regarding COVID-19 among pregnant or postpartum women include:

i) describe the natural history of COVID-19; ii) estimate the incidence of and risk factors for

hospitalization, admission to intensive care unit, receipt of critical care, and use of invasive

ventilation (for COVID-19); and iii) estimate the infection and case fatality rate. For each of

these outcomes, we will also compare the risk for pregnant women with COVID-19 to non-

pregnant women of reproductive age with confirmed or suspected COVID-19.

Specific objectives regarding maternal health among pregnant or postpartum women

with COVID-19 are to estimate the incidence or prevalence of: i) maternal morbidities including

hypertensive disorders of pregnancy, abnormal placentation, preterm prelabor rupture of

membranes, hemorrhage, embolic disease, etc. ; ii) maternal and pregnancy-related death; iii)

adverse pregnancy outcomes including stillbirth, preterm birth, small-for-gestational age birth,

and low birthweight. For each of these outcomes, we will also compare the risk for pregnant

women with COVID-19 to other pregnant women without COVID-19.

Specific objectives regarding newborn health among newborns born to patients with

COVID-19 are to estimate the incidence and timing of and risk factors for: i) congenital

anomalies; ii) perinatal and (early) neonatal mortality; and iii) intrauterine, intrapartum, or early

peripartum transmission of SARS-CoV-2 from mother to child. When appropriate, we will

compare these risks to those of newborns born to women without COVID-19 during pregnancy.

Specific objectives regarding SARS-CoV-2 in biospecimens (e.g. nasopharyngeal,

vaginal, or rectal swab, maternal blood, pregnancy tissue, placenta, amniotic fluid, cord blood,

breast milk) include estimating: i) the proportion of biospecimens with detectable SARS-CoV-2

virus and median viral load; ii) the association between virus or viral load in biospecimen and

key outcomes described above.

Search strategy & study inclusion

We originally recruited study sites to join the proposed prospective meta-analysis first via

professional research networks, and subsequently via key stakeholder networks. Stakeholders

at the National Institute of Child Health and Human Development (NICHD) at the U.S. National

Institutes of Health (NIH) supported recruitment of NIH-funded maternal and child health

network groups and other U.S. government funded projects. Stakeholders at the World Health

Organization (WHO) in the Departments of Maternal, Newborn, Child, and Adolescent Health

(MNCAH) and of Sexual and Reproductive Health and Research (SRH) supported recruitment

of researchers engaged in the COVID-19 MNCAH research network and the SRH pregnancy

cohorts working group [20]. Stakeholders from the International Federation of Gynecology and

Obstetrics (FIGO) supported recruitment by issuing an invitation through their international

network. Studies were invited to participate based solely on study design. Eligible study designs

included: i) registries enrolling all suspected or confirmed cases in pregnancy or postpartum

period, ii) cohorts enrolling all pregnant women, or iii) case-control studies enrolling pregnant or

postpartum women with suspected or confirmed COVID-19. There were no *a priori* sample size

limitations due to the dynamic epidemiology of the pandemic. Study investigators confirmed

their intent to contribute to the PMA via a letter of intent or signing a collaboration agreement.

Building on concepts laid out in the Framework for Adaptive Meta-analyses (FAME) [21],

we will also collaborate with the PregCOV-19 Living Systematic Review Consortium to identify

studies that might be eligible for post-publication inclusion into the proposed meta-analysis. The

search strategy for the LSR was previously published [8,22]. We will screen all published

studies included in the living systematic review for potential inclusion in the PMA using the

following criteria: i) the study conforms to the study designs outlined above; ii) there is a defined

catchment area (e.g., certain hospitals, states, etc.); and iii) the sample size included at least 25

pregnant or postpartum people with confirmed or suspected COVID-19 who were consecutively

recruited or identified through surveillance.

Exposure (Suspected or Confirmed SARS-CoV-2 Infection)

Confirmed cases of COVID-19 will be defined as those with laboratory-confirmed SARS-

CoV-2 infection via a nucleic acid amplification test, regardless of clinical signs or symptoms.

The original protocol was expanded to include COVID-19 cases confirmed via antigen tests as

they became validated and widely used over the course of the pandemic. Suspected cases will

be defined according to the WHO August 7, 2020 case definition based on either a) clinical

(acute onset fever and cough, or acute onset of three or more pre-identified signs and

symptoms) and epidemiological criteria (residing, working, or traveling in an area with high risk

of transmission or community transmission in the past 14 days or working in any health care

setting) or the severe acute respiratory illness (SARI) case definition [23]. Probable COVID-19

infections will also be defined according to the WHO August 7, 2020 case definition (clinical

criteria and contact with a case; a suspected case with chest imaging, recent anosmia or

ageusia onset without other cause, respiratory disease preceding death and contact with a

case) [23].

Outcomes of Interest

Outcomes related to women's health will include:

- Mortality: all-cause mortality, COVID-19 specific mortality, and pregnancy-related and maternal mortality;
- COVID-19 related clinical signs and symptoms: fever, cough, shortness of breath, dizziness or fainting, body aches, runny nose, sore throat, loss of sense of smell, loss of sense of taste, sneezing, fatigue, nausea, vomiting, diarrhea, and headache;
- Morbidity and healthcare utilization related to COVID-19 severity: pneumonia diagnosis, hospitalization, admittance to an intensive care unit (ICU), or use of critical care interventions;
- Pregnancy-related morbidities: hypertensive disorders of pregnancy including gestational hypertension, preeclampsia, eclampsia, hyperemesis gravidarum, fetal growth restriction, abnormal placentation (placenta previa and placenta accreta spectrum), placental abruption, preterm labor, preterm prelabor rupture of membranes, hemorrhage (antepartum/intrapartum; postpartum; abortion-related), embolic disease, or anesthetic complications. We also collected data on cesarean delivery.
- Adverse pregnancy outcomes: stillbirth (fetal death $\geq$28 weeks' gestation per WHO definition), early preterm birth (<34 weeks gestation), preterm birth (<37 weeks gestation), small-for-gestational-age birth (<3rd and <10th percentile per the INTERGROWTH-21st newborn reference values) [24], short-for-gestational-age birth (<3rd and <10th percentile per the INTERGROWTH-21st newborn reference values on length [25], low birthweight (<2500 grams), and very low birthweight (<1500 grams).
- Presence of SARS-CoV-2 and viral load in maternal biological specimens including: amniotic fluid, placenta (maternal or fetal side), cord blood, vaginal swab, feces or rectal

swab, nasopharyngeal swab, pregnancy tissue (fetus or pregnancy sac and placenta) in

the case of stillbirth or abortion, breastmilk, and maternal blood.

Neonatal outcomes of interest include:

● Congenital anomalies: neural tube defects, microcephaly, congenital malformations of

ear, congenital heart defects, orofacial clefts, congenital malformations of digestive

system, congenital malformations of genital organs, abdominal wall defects,

chromosomal abnormalities, reduction defects of upper and lower limbs, or talipes

equinovarus (clubfoot);

● Early neonatal (<7 days) and neonatal (<28 days) death;

● Perinatal death (stillbirth (>28 weeks) or early neonatal death (<7 days);

● Admission to and length of stay in neonatal intensive care unit (NICU);

● Mother-to-child transmission of SARS-CoV-2 (differentiating intrauterine versus

intrapartum or early peripartum infection if possible).

Data Harmonization

We developed the draft data modules and questions in April 2020 based on a proposed

set of questions from the Pregnancy CoRonavIrus Outcomes RegIsTrY (PRIORITY) study

(ClinicalTrials.gov Identifier: NCT04323839). We also reviewed and included questions from the

case report and data collection forms developed by the Department of Sexual and Reproductive

Health (SRH), HRP, WHO and the WHE, WHO prospective cohort study, and the U.S. Centers

for Disease Control and Prevention (CDC) Surveillance for Emerging Threats to Mothers and

Babies Network (SET-NET) study [26,27] . We requested two rounds of feedback via a survey

and by email from the >50 participants of the bi-monthly informal meeting established at the

beginning of the pandemic called the "Perinatal COVID-19 Global Gathering". The current data

modules reflect feedback and general consensus among survey respondents. The final draft of

the data modules and core variables was finalized and shared broadly on June 2, 2020 (S File

1). We updated the data modules in September 2020 to reflect evolving understanding of

SARS-CoV-2 infection in newborns and to reflect the updated SRH, HRP, WHE UNITY generic

protocol developed by WHO for COVID-19-related pregnancy cohort studies [26] (S File 2).

Data Sharing & Study-Specific Data Analysis

We will develop a codebook and statistical codes for each contributing study to map

original study variables to the PMA core variables. Investigators can join the PMA either by

submitting individual patient data or running standardized code to generate aggregate data

estimates that can be included in the meta-analysis. The same data quality and consistency

checks will be performed for each study, and any issues will be resolved with study

investigators. Studies will be eligible to contribute data to the PMA when they have accrued at

least 25 confirmed cases with completed follow up.

Study-specific estimates for the two-stage meta-analysis will be produced using

standardized analytical codes, and aggregated measures will be exported into a database for

the meta-analyses. Individual studies are expected to proceed with their own study publications

and can use any analyses generated by the PMA for publication or policy making in their study

context.

Overlapping Data

For each updated meta-analysis, we will review included studies for potentially

overlapping participants to avoid including individual participants in the estimates for more than

one study. We will choose a single study to contribute cases from given locations (e.g. health

facilities, cities, states, or countries). The study with the most complete data will be selected to

contribute, or in the case of similar data between studies, we will include data from the study

that was the first to join the PMA. The number of studies and the number of cases per study is

therefore likely to change with each updated meta-analysis, given this robust analytical strategy.

We will use a modified version of the Newcastle Ottawa Scale to assess the risk of bias of

individual studies.

Methods for Data Synthesis

Ideally, all individual-level data would be combined for one-stage meta-analysis.

However, we anticipate that the ability to quickly share data and the degree of willingness to

share individual patient data may vary by country and across collaborators and institutions.

Thus, we will plan for a step-wise statistical analysis plan where the most feasible and simple

analyses (that contribute directly to our research questions) are prioritized, and more advanced

statistical modelling will be conducted subsequently.

For the first stage of analysis, prevalence, and incidence data for the respective

outcomes, overall and by risk factor, will be pooled using the conventional DerSimonian-Laird

random-effects model [28]. For analyses where only proportions or crude incidence rates are

used, the Arcsine method may be applied to stabilize the statistics and ensure approximate

asymptotic normality [29]. For analyses comparing pregnant COVID-19 cases to a) COVID-19

negative pregnancies or b) non-pregnant women with COVID, we will calculate the relative risk

or odds ratio (for case-control studies) for each outcome; effect estimates will be pooled using

the conventional DerSimonian-Laird random-effects model [28]. We will assess forest plots

visually for heterogeneity. When at least ten studies are being pooled, we will also quantify

heterogeneity by the I^2 statistic [30].

Analysis of Subgroups

Where appropriate and as sample size allows, we will consider meta-regression or

subgroup analyses by the following study level characteristics: study design and sampling

strategy, proportion of confirmed COVID-19 cases (out of suspected and confirmed cases),

national maternal mortality ratio, national neonatal mortality rate, and geographic region. We will

also consider subgroup analysis by the following individual patient characteristics to identify risk

factors or effect modifiers for specific outcomes: confirmed versus suspected COVID-19 case

status; gestational age at COVID-19 onset (by week or by trimester), COVID-19 severity, pre-

pregnancy health conditions or comorbidities [diabetes, hypertension, cardiovascular disease,

obesity (Body Mass Index $\geq$30 kg/m^2), underweight (Body Mass Index <18.5 kg/m^2),

tuberculosis, malaria, HIV/AIDS, syphilis, anemia (hemoglobin < 11 g/dL)], maternal morbidities

(also described above as outcomes), maternal vaccination status (influenza, COVID-19),

calendar time or time since first COVID-19 diagnosis in the study area, parity, maternal age,

race or ethnicity, and maternal education. Some of these risk factors may be considered both

outcomes of having COVID-19 in pregnancy or factors that exacerbate SARS-CoV-2 infection in

pregnancy; we will attempt to disambiguate between the two based on the timing of diagnoses

whenever possible.

Sample size considerations

Consistent with the GRADE event-based approach, we will avoid "very low precision" by

requiring a minimum number of three sites or a total of 100 events for each outcome to run the

first analysis [31]. As data accumulate, we will evaluate the robustness of the inferences and

whether the answer can be reasonably inferred via a conservative sample size. Assuming at

least 50% heterogeneity between sites, the need for 90% power and 5% type 1 error to detect a

difference, a conservative 1% prevalence/incidence and a risk ratio of 1.5 for the considered

subgroup, a minimum of 30,000 participants are required to demonstrate an effect for each

outcome and the proposed subgroups (risk factors). Alternatively, a total of 400 events or more

may be used as a threshold for 'sufficient evidence' in accordance with recommendation of the

GRADEPROfiler [31,32]. When these thresholds are met, the steering committee must decide

whether additional, updated meta-analyses will be performed.

Governance

The steering committee will consist of at least one member from each participating site,

key stakeholders (S File 3), and the technical coordinating team at the George Washington

University. When a formal vote is needed, the following teams will each cast one official vote:

each group of investigators linked to participating studies, each key stakeholder organization,

and the technical coordinating team. The steering committee will prioritize research questions

and agree on common elements of data collection. They will disseminate results, including rapid

reports to key stakeholders, webinars, and submission of manuscripts to preprint servers and

scientific journals. The technical coordinating team will develop protocols for data transfer and

ensure data quality; write the statistical analysis plans; and conduct meta-analyses.

Participating studies

At the time of publication, 25 studies (in 41 countries) were actively participating in the

ongoing PMA (Table 1). Among these studies, 11 have a contemporaneous comparison group

of pregnancies without COVID-19; two studies include a comparison group of non-pregnant

women of reproductive age. The median anticipated sample size of participating studies is

1,500.   More   than   76,000   pregnancies

in total are expected to contribute to the completed meta-analyses (Table 1). These studies

include data from 41 countries: Argentina, Australia, Bangladesh, Belgium, Brazil, Canada,

Chile, China, Colombia, Democratic Republic of the Congo, Egypt, France, French Guyana, The

Gambia, Germany, Ghana, Guatemala, Hong Kong, India, Israel, Italy, Kenya, Lebanon, Mali,

Mexico, Mozambique, Netherlands, New Zealand, Nigeria, Pakistan, Peru, Portugal, Puerto

Rico, Rwanda, South Africa, Spain, Sweden, Switzerland, Turkey, Uganda, United Kingdom,

United States, and Zambia (Fig 1). Data from additional countries is expected from the WHO

prospective cohort study and other studies that will be identified via the published literature. A

description of each study, including the study investigators and institutional affiliations, study

design description, recruitment methods, anticipated sample sizes, recruitment timeline, and

primary outcomes are presented in supplementary tables (S3 File).

Table 1. Characteristics of participating studies

Study	Country of Study	Anticipated Sample Size (Pregnant Women)	Pregnant COVID-19 Case Recruitment Strategies					Comparison Group		
			Universal COVID-19 Screening		COVID-19 Care					
			Labor & Delivery	Antenatal Care	Hospitalized for COVID	Outpatient Care for COVID-19	Testing Site (Symptoms or Exposure)	None	Non-COVID-19 Pregnancies	Non-pregnant COVID-19 cases
AFREHealth	Multiple[1]	350			X				X	X
ANCOV Kenya	Kenya	2500	X	X		X	X		X	
ARTIST India	India	300	X	X			X	X		
CanCOVID-Preg	Canada	6000	Mixed		X	X	X		X	X
Cerner Real World Data	USA	5000	Mixed						X	
China/Hong Kong	China, Hong Kong	146	X		X		X	X		
CHOPAN Australia	Australia, New Zealand	50						X		
COVI-Preg	Multiple[2]	1700	X		X	X	X		X	
Gestacovid Chile	Chile	1500	X	X	X	X	X	X		
Madrid Registry	Spain	200	X	X			X	X		
Mali ANC + Surveillance	Mali	3000		X		X	X		X	
Mali ANC Case-Control	Mali	1500		X					X	
Mexico National Registry	Mexico	11031	X		X					X
NICHD Global Network	Multiple[3]	20,000	Random Sample						X	
NICHD MFMU Network	United States	14,000	Most	X	X	X	X		X	
PANCOVID	Multiple[4]	8263	X		X	X		X		
PERICOVID (PRECISE)	Multiple[5]	6000		X					X	X
PERICOVID (PREPARE)	Multiple[6]	400	X	X	X	X	X		X	

PRIORITY USA	United States	1500	X	X	X	X	X	X
Puerto Rico CASSS	Puerto Rico	458	X			X	X	X
RECOGEST Colombia	Colombia	500			X		X	X
Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome	Italy	230	X		X	X		X
UKOSS	United Kingdom	7000	X		X		X	X
Washington State COVID-19 in Pregnancy Collaborative	USA	240	X[7]		X	X	X	X
WHO Prospective Cohorts	Multiple[8]	>16,000	X	X	X	X	X	X

1 Democratic Republic of the Congo, Ghana, Kenya, Nigeria, South Africa, and Uganda

2 USA, Canada, Mexico, Colombia, French Guyana, Peru, Brazil, Argentina, Chile, Australia, Rwanda, Lebanon, Israel, China, Portugal, Spain, France, Italy,
United Kingdom, Switzerland, Germany, Belgium, Netherlands, Ireland, and Egypt

3 India, Pakistan, Bangladesh, Kenya, DRC, Zambia, and Guatemala

4 United Kingdom, Albania, Argentina, Austria, Chile, China, Czech Republic, Egypt, Greece, Hong Kong, Indonesia, India, Italy

5 The Gambia, Mozambique, and Kenya

6 Uganda, Malawi

7 Universal testing prior to labor & delivery admission was not uniform across all participating clinical sites, but occurred in the majority by May of 2020. The
remaining hospitals initiated universal testing for scheduled delivery admissions only.

8 The generic protocol for the WHO prospective cohort study is available for countries at: https://www.who.int/publications/m/item/a-prospective-cohort-study-
investigating-maternal-pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2. The final list of participating countries that will
contribute to the meta-analysis is being confirmed.

Fig 1. Map of participating study sites

Discussion

Our sequential, prospective meta-analysis aims to pool individual patient data from ongoing or completed studies, registries, and surveillance programs that identify SARS-CoV-2 infections in pregnancy and postpartum.

There are several benefits to our approach, which is guided by the principles of flexibility, robustness, collaboration, and inclusion. Early efforts to plan for pooling can reduce research waste (e.g., incompatible data, duplication of efforts) and improve the collective value of data [33]. Through collaboration since April 2020, including participation in WHO-coordinated working groups, we have developed and shared data collection tools and standardized some data collection components while several participating studies were starting their respective research. Ongoing pooling has also highlighted where data elements are missing or sparse across studies, thus providing justification for additional effort from study investigators to retrospectively extract additional data or modify their data collection forms. Further, this collaborative approach of pooling data highlights the possibility of generating robust answers to questions of collective importance at a global scale [34,35]. We are also more likely to elucidate risks related to rare outcomes. Collaboration is especially important for achieving scientific consensus regarding special populations—such as pregnant patients and newborns—who may not be specifically considered in national surveillance programs and may be actively excluded from other clinical research.

Our approach uses statistical methods for individual patient data meta-analysis, which is generally considered to be the gold standard in pooling data given the many steps used to ensure quality and consistency of the data and analyses. All data will be reviewed with the same data quality assessments, and outliers will be assessed consistently across studies. Analysis definitions will be standardized across studies. This is especially important given that for many

outcomes, study definitions vary between countries (e.g. whether a woman should receive

critical care, the gestational age cutoff for defining stillbirth). Furthermore, we will avoid duplicate

case counting by working with and reanalyzing data from studies that include overlapping health

facilities and centers that contribute to two or more studies. This has been a major issue in

COVID-19-related meta-analyses because much scientific literature is based on case reports or

case series; the same cases sometimes appear in multiple published papers. Traditional meta-

analyses based on the published literature cannot resolve these methodological issues.

Importantly, this approach is robust, flexible and collaborative. Each set of investigators

can implement their own protocol, offering more flexibility to design a study specific to a given

setting. Investigators can also proceed with their own study publications, thus ensuring an

opportunity to be explicit about the local context in which the data collection took place and

clearly take the credit associated with authorship. Our basic analyses will be done as a two-

stage meta-analysis, allowing us flexibility in how data is shared. Studies that are willing and

able can share their individual patient data directly with the data coordinating team for central

analysis. Alternatively, studies that are unwilling or unable to share individual patient data can

appoint their own study-specific data analyst to join the PMA data coordinating team. This

approach to a "distributed" individual patient data meta-analysis meets data sharing needs for

different groups, and hopefully ensures that anyone can participate. Finally, our regular steering

committee meeting allows for joint decision-making about which analyses should be prioritized

and when to move forward with publications. We hope to be responsive to emerging, policy-

relevant questions, such as the safety and efficacy of vaccination in pregnancy.

Conclusion

Prospective meta-analyses offer a rigorous way to generate definitive answers to emerging questions. In the current context of the COVID-19 pandemic, there is limited high-quality data that can be pooled in order to inform public health guidance and healthcare strategies, specifically for pregnant women and their newborns. The proposed study will contribute necessary information for evidence-based decision-making related to COVID-19 and maternal and neonatal health.

Author Contributions

ES, EO, SH, JMT were involved in the conceptualization and methodology; ES, EO were responsible for data curation; ES, VF, YA were responsible for funding acquisition; ES led investigation and writing the original draft manuscript; EO, SH contributed to the writing – original draft preparation; ES, EO conducted the analysis; EO, RZ contributed to visualization; ES, JMT provided supervision. EO, SH, RZ, KF, LM, and GWG contributed to project administration. All authors contributed to writing – review & editing.

References

1   Johns Hopkins University. COVID-19 map-Johns Hopkins Coronavirus Resource Center. 2020.https://coronavirus.jhu.edu/map.html

2   The true death toll of COVID-19: estimating global excess mortality. https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-

554  mortality (accessed 26 Jul 2021).

555 3 CDC. Coronavirus Disease 2019 (COVID-19). 2020.https://www.cdc.gov/coronavirus/2019-
556   ncov/need-extra-precautions/people-with-medical-conditions.html (accessed 16 Sep 2020).

557 4 (hq) WH. COVID-19 Clinical management: living guidance.
558   2021.https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (accessed 26
559   Jul 2021).

560 5 Sappenfield E, Jamieson DJ, Kourtis AP. Pregnancy and susceptibility to infectious
561   diseases. *Infect Dis Obstet Gynecol* 2013;**2013**:752852.

562 6 Lam CM, Wong SF, Leung TN, *et al.* A case-controlled study comparing clinical course and
563   outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome.
564   *BJOG* 2004;**111**:771–4.

565 7 Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from Coronavirus 2019-
566   nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other
567   Human Coronavirus Infections. *Viruses* 2020;**12**:194.

568 8 Allotey J, Stallings E, Bonet M, *et al.* Clinical manifestations, risk factors, and maternal and
569   perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and
570   meta-analysis. BMJ. 2020;:m3320. doi:10.1136/bmj.m3320

571 9 Metz TD, Clifton RG, Hughes BL, *et al.* Disease Severity and Perinatal Outcomes of
572   Pregnant Patients With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol*
573   2021;**137**:571–80.

574 10 Villar J, Ariff S, Gunier RB, *et al.* Maternal and Neonatal Morbidity and Mortality Among
575   Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational
576   Cohort Study. *JAMA Pediatr* Published Online First: 22 April 2021.
577   doi:10.1001/jamapediatrics.2021.1050

578 11 Ellington S, Strid P, Tong VT, *et al.* Characteristics of Women of Reproductive Age with
579   Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January
580   22-June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:769–75.

581 12 Farrell R, Michie M, Pope R. Pregnant Women in Trials of Covid-19: A Critical Time to
582   Consider Ethical Frameworks of Inclusion in Clinical Trials. *J Empir Res Hum Res Ethics*
583   2020;**42**:17–23.

584 13 Sexual and Reproductive Health and Research. Definition and categorization of the timing
585   of mother-to-child transmission of SARS-CoV-2.
586   2021.https://www.who.int/publications/i/item/WHO-2019-nCoV-mother-to-child-
587   transmission-2021.1 (accessed 2 Sep 2021).

588 14 Kimberlin DW, Stagno S. Can SARS-CoV-2 Infection Be Acquired In Utero?: More
589   Definitive Evidence Is Needed. *JAMA* 2020;**323**:1788–9.

590 15 Mahyuddin AP, Kanneganti A, Wong JLJ, *et al.* Mechanisms and evidence of vertical
591   transmission of infections in pregnancy including SARS-CoV-2. *Prenat Diagn* Published
592   Online First:

2020.https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/pd.5765?casa_token=7xnIU0uz
zAgAAAAA:lIT283_cYNKnvzUvkGQ0iMhbS9R0HJkLnu640BWid2pQGWPorHSyel_VRhBx
J1UaNt9LitF-PDUCPQ

16   Carosso A, Cosma S, Serafini P, *et al.* How to reduce the potential risk of vertical
transmission of SARS-CoV-2 during vaginal delivery? *Eur J Obstet Gynecol Reprod Biol*
2020;**250**:246–9.

17   Knight M, Bunch K, Vousden N, *et al.* Characteristics and outcomes of pregnant women
admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based
cohort study. *BMJ* 2020;**369**:m2107.

18   Liu W, Wang J, Li W, *et al.* Clinical characteristics of 19 neonates born to mothers with
COVID-19. *Front Med* 2020;**14**:193–8.

19   Higgins JPT, Thomas J, Chandler J, *et al. Cochrane Handbook for Systematic Reviews of
Interventions.* John Wiley & Sons 2019.

20   Maternal, Newborn, Child and Adolescent health, Ageing and COVID-19.
https://www.who.int/teams/maternal-newborn-child-adolescent-health-and-ageing/covid-19
(accessed 26 Jul 2021).

21   Tierney J, Vale CL, Burdett S, *et al.* Timely and reliable evaluation of the effects of
interventions: a framework for adaptive meta-analysis (FAME). *Trials* 2017;**18**:132–3.

22   Yap M, Debenham L, Kew T, *et al.* Clinical manifestations, prevalence, risk factors,
outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and
postpartum: a living systematic review protocol. *BMJ Open* 2020;**10**:e041868.

23   Definitions C. WHO COVID-19: Case Definitions.

24   Papageorghiou AT, Ohuma EO, Altman DG, *et al.* International standards for fetal growth
based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the
INTERGROWTH-21st Project. *Lancet* 2014;**384**:869–79.

25   Villar J, Ismail LC, Victora CG, *et al.* International standards for newborn weight, length,
and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of
the INTERGROWTH-21st Project. *Lancet* 2014;**384**:857–68.

26   A prospective cohort study investigating maternal, pregnancy and neonatal outcomes for
women and neonates infected with SARS-CoV-2. World Health Organization 2020.
https://www.who.int/publications/m/item/a-prospective-cohort-study-investigating-maternal-
pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2
(accessed 26 Jul 2021).

27   CDC. Investigating the Impact of COVID-19 during Pregnancy.
2021.https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-
populations/pregnancy-data-on-covid-19/what-cdc-is-doing.html (accessed 26 Jul 2021).

28   DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;**7**:177–88.

29   Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses
with binary outcomes. *Stat Med* 2008;**27**:746–63.

30   Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
2002;**21**:1539–58.

31   Guyatt GH, Thorlund K, Oxman AD, *et al.* GRADE guidelines: 13. Preparing Summary of
Findings tables and evidence profiles—continuous outcomes. Journal of Clinical
Epidemiology. 2013;**66**:173–83. doi:10.1016/j.jclinepi.2012.08.001

32   Guyatt GH, Oxman AD, Kunz R, *et al.* GRADE guidelines 6. Rating the quality of
evidence—imprecision. *J Clin Epidemiol* 2011;**64**:1283–93.

33   Seidler AL, Hunter KE, Cheyne S, *et al.* A guide to prospective meta-analysis. *BMJ*
2019;**367**:l5342.

34   Smith ER, Flaherman VJ. Why you should share your data during a pandemic. *BMJ Glob*
Health 2021;**6**. doi:10.1136/bmjgh-2021-004940

35   Petkova E, Antman EM, Troxel AB. Pooling Data From Individual Clinical Trials in the
COVID-19 Era. *JAMA* 2020;**324**:543–5.

Supporting information

648   **S1 File. Data modules and core variables - version June 2, 2020**

649   **S2 File. Data modules and core variables - version November 8, 2020**

650   **S3 File. Description of participating studies and key stakeholders**

Participating Study Sites

■ Data collection sites